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Scafring following wounding is a major medical
problem. In skin wounds or bums scarring often leads
to adverse cosmesis and consequent psychological
problems, adverse functionparticularly overjoints and
retardation of growth especially in children. Scarring
in muscle adversely affects movement and can cause
ankylosis. In abdominal andpelvic organs scarring can
lead to life threatening strictures and adhesions. In the
eye, scarring can cause blindness, whilst in the central
nervous system scarring inhibits neuronal
reconnection and hence restoration of neuronal
function. In almost every organ and tissue, scarring
following injury or trauma is a major problem, for
which there are no good preventative or therapeutic
regimens.
Several years ago, we and other researchers observed
that skin wounds made in early embryos/fetuses of
reptilian, avian and mammalian species healed
without scarring. My laboratory subsequently
embarked upon a detailed analysis of the cellular and
molecular basis of scar-free healing in embryos
compared to scar forming healing in adults.
Investigations using embryonic and fetal mice
revealed that incisional wounds made in embryos and
fetuses, up to approximately the first half or 2/3 of
gestation, healed without scarring. Wounds made
during the last trimester of pregnancy or in early
postnatal life showed progressively worse scarring.
Thus, there is a temporal cut off for scar-free healing
during late embryonic or early fetal life.
The phenomenon of scar-free embryonic healing does
not depend on the special intra uterine environment
e.g. warm, sterile, uniform 37°C, bathed in the
amnoitic fluid. At least two lines of experimentation
indicate that the fetal environment is unimportant for
scar-free healing. First, adult skin grafted onto a fetus
and subsequently wounded heals with a scar, whereas
corresponding control fetal grafts heal without
scarring. Conversely, embryonic skin grafted into
subcutaneous locations in the adult heals without
scarring. Second, experimentation on new born
marsupials indicated that incisional wounds made
within the first four days of the embryo attaching to
the nipple on the marsupial, heal without scarring. The
new born marsupials are not bathed in aminiotic fluid,
are frequently in a microbiologically rich environment
(from maternal faeces and urine) but like the late
embryo or early fetus, have a very poorly developed
immune system, howeverunlike the eutherian embryo
or fetus, they have highly differentiated skin.
There are many cellular and molecular differences
between scar-free embryonic healing and scarforming
adult healing. One critical difference is the
inflammatory response. Embryos mount a poor
inflammatory response to wounding with the
recruitment of only small inflammatory cells e.g.
monocytes and macrophages to the wound site and
even smaller numbers of mature activated cells.
Consequently, the types and quantities of growth
factors present in the embryonic wound compared to
the adult wound are quite different. Embryonic
wounds have a very low levels, for example, of
transforming growth factors beta-I andbeta-2 whereas
adult wounds have a very high early levels ofTGFB1
and TGFB2 (released from degranulating platelets and
subsequently from recruited monocytes and
macrophages).
Using the information gleaned from these molecular
and cellular investigations comparing scar-free
embryonic healing and scar forming adult healing, we
have experimentally manipulatedadultrodent, porcine
and human wounds in an attempt to ameliorate or
prevent scarring.
Inthe first series ofexperiments, we demonstrated that
neutralising antibodies to transforming growth factor
beta-i and beta-2 (TGFB1 and TGFB2) injected
intradermally at the wound site could prevent
subsequent scarring. Dose response and time response
experiments showed that the neutralising antibodies
hadtobe appliedimmediatelybefore, atthe time of, or
immediately after wounding to achieve maximum
effect. In fact the timing of any scar preventing
therapy is critical. The best results are obtained if the
therapy is applied before, at the time of, or
immediately after wounding. This is a real biological
phenomenon. All growth factors such as TGFB1 and
TGFB2 operate as auto inductive cascades. A small
initial amount of TGFB1 released from degranulating
platelets is chemotactic to monocytes and
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macrophages which migrate to the wound site and
secrete further TGFB1 and 2. TGFB1 is also
autocatalytic, binding it to its own promoter and
upregulating its own synthesis. There, thus exists a
large amplification cascade. Consequently,
neutralisation of a small amount of the growth factor
early in the wound healing process leads to major
effects later on. Moreover, in the early phases of
wound healing, many key processes are regulated by a
small number ofgrowth factors, such as those released
from degranulating platelets. However, within a few
days of wounding, complex interacting networks of
cytokine responses areestablished, suchthatitis much
morediffilculttoobtaineffects outofmanipulating one
or two cytokines: effects that can be produced early in
the wound healing response before the interacting
redundant cascades become established.
Neutralising antibodies to TGFB1 and TGFB2
markedly decrease scarring, such that there is no
microscopic evidence of where the incisional wound
was made and the dermal architecture is restituted to a
normal basket weave pattern. Neutralising antibody
therapy also reduces the number of monocytes and
macrophages atthe wound site, decreases the numbers
of blood vessels and also decreases the early wound
fibronectin content: effects which are consistent with
low levels of transforming growth factor beta-i and
beta-2. By using isoform specific antibodies, we have
determined that neutralisation oftransforming growth
factors beta-i and beta-2 is required to give optimal
anti-scarring effects. Neutralisation of TGFB3 has no
anti-scarring effect atbest andmakes the scar worse in
some instances. Conversely, addition of exogenous
TGFB3 at the time of, or immediately after, wounding
results in a marked improvement in scarring. It is
therefore the ratio between TGFB3 on the one hand
and TGFB1 and TGFB2 on the other which is
important for scar formation. Decreasing the levels of
TGFB1 and TGFB2 relative to TGFB3 appears to be
the key to the anti-scarring therapy. This conclusion is
supported by wound healing studies in transgenic
mice, which either under or over-express TGFB1 or
TGFB3. Antisense oligonucleotides to TGFB1 and
TGFB2 administered before wounding also prevent
subsequent scarring. For the antisense oligonucleotide
therapy it is essential to deliver the antisense
oligonucleotides before wounding and therefore this
therapy is only applicable to elective surgery (the most
common form of trauma). The antisense
oligonuclcotide technology takes advantage of the
transient permeabilisation ofcells which occurs during
wounding to achieve very high loading of the
antisense oligonucleotides into target cells.
These studies have led to new therapeutic regimes
which have been tested in experimental rodents and
pigs and are now entering human clinical trial.
Reagents in human clinical trial for anti-scarring e.g.
in the central nervous system, the eye or the skin,
currently include recombinant human phage
neutralising antibodies to TGFB2 and TGFB1,
antisense oligonucleotides to TGFB1 and 2, TGFB3
and plasmids expressing TGFB3 for gene therapy.
Transforming growth factor beta family members like
most growth factors, are made as an inactive
precursor. This precursor is subsequently activated by
proteolytic cleavage to produce the active growth
factor. Activation is therefore a key biological
regulatory step. In the case of TGFB1, it is initially
secreted as an inactive precursor associated with a
larger protein transcribed from the same gene entitled
'the latency associated protein' (LAP). This LAP has
three carbohydrate chains on two of which the
terminal residues are the sugar Mannose-6-Phosphate.
Activation of transfonrning growth factor beta is
complex but depends in part on bonding of the
Mannose-6-Phosphate /TGF-2 receptor, followed by a
conformational change in the molecule, exposure of a
protease sensitive site and cleavage of the active
TGFB1 from the inactive LAP precurser. We have
demonstrated that exogenous administration of
Mannose-6-Phosphate can competitively inhibit
binding ofthe TGFB latency associated peptide at the
Mannose-6-Phosphate receptor, thus preventing
activation of TGFB1 and hence inhibit scarring. The
mode of delivery of the Mannose-6-Phosphate is
crucial as the molecule is rapidly metabolised and
appropriate vehicles have to be used to achieve the
requisit tissue levels over the post-wounding period.
However, single applications ofMannose-6-Phosphate
in an appropriate vehicle at the time of wounding can
markedly prevent scarring. These applications also
reduce the number of monocytes and macrophages,
blood vessels and early fibronectin content of the
wounds similar to the effects seen with neutralising
antibodies to TGFB1 and TGFB2. Mannose-6-
Phosphate as an anti-scarring agent is currently in
human clinical trial.
Manipulation of the levels of other growth factors,
such as platelet derived growth factor and several
interleukins early in the wound healing cascade can
also have a scar modulating effect.
In parallel with the development of these novel
antiscarring therapies, we have also devised both
clinical and histological quantitative scales for the
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assessment of scarring. These scales include validated
visual analogue scales for the assessment of the
macroscopic features ofscarring, together with similar
scales for the assessment of histological scarring and
the development of three dimensional image analysis
to quantitate changes in the structure of the dermis in
man and animals.
Interestingly, our studies of ageing rodents and
humans have demonstrated that the maximum
inflammatory response and hence cytokine profile is
present in young adults who scar worst. Conversely, in
old age, the inflammatory response is reduced. The
growth factor profile differs both quantitatively and
qualitatively (with decreased levels of TGFB1 and
TGFB2 and increased levels ofTGFB3) andthe quality
of scarring is markedly improved. There are major
differences in healing speeds and quality between
males and females with age and between pre and post-
menopausal females, indicating the importance of the
hormonal milieu.
We hypothesise that acute wounds are
phylogenetically optimised for speed ofhealing under
dirty conditions. The evolutionary response is to
maximise the inflammatory response and put into
overdrive the cytokine cascade. This ensures that the
wound heals very quickly and has multiple redundant
mechanisms. This is doubtless important to prevent
further bleeding from minor trauma or septicaemia
from a slowly healing wound. However, this massive
inflammatory response swamps out the endogenous
regenerative capacity of the dermis and results in
scarring. With contemporary hygiene, we can
modulate this early cytokine profile, changing the
ratios of various growth factors and cytokines. Such
manipulated wounds heal just as quickly with no
evident signs ofinfection but with markedly improved
scarring. Such studies indicate that there is a wide
therapeutic window for the control ofscarring in man,
as this is something which evolution has not
optimised. Interestingly, similarmechanisms appearto
operate in chronic fibrotic disorders, such as
pulmonary fibrosis, liver cirrhosis, glomerular
nephritis, indicating thatfundamental investigations of
the basis of dermal scarring and how it might be
prevented may have a more widespread application in
many common human fibrotic disorders.
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